Cargando…
Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical Trial
Despite the widespread availability of effective vaccines, new cases of infection with severe acute respiratory syndrome coronavirus-2, the cause of coronavirus disease 2019 (COVID-19), remain a concern in the settings of vaccine hesitancy and vaccine breakthrough. In this randomized, controlled, ph...
Autores principales: | Coppock, Dagan, Violet, Pierre-Christian, Vasquez, Gustavo, Belden, Katherine, Foster, Michael, Mullin, Bret, Magee, Devon, Mikell, Isabelle, Shah, Lokesh, Powers, Victoria, Curcio, Brian, Monti, Daniel, Levine, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8954118/ https://www.ncbi.nlm.nih.gov/pubmed/35330204 http://dx.doi.org/10.3390/life12030453 |
Ejemplares similares
-
Correction: Coppock et al. Pharmacologic Ascorbic Acid as Early Therapy for Hospitalized Patients with COVID-19: A Randomized Clinical Trial. Life 2022, 12, 453
por: Coppock, Dagan, et al.
Publicado: (2022) -
Pharmacologic Ascorbate in Myeloma Treatment: Doses Matter
por: Violet, Pierre-Christian, et al.
Publicado: (2017) -
Epigenetic effects of pharmacologic ascorbate
por: Steers, Garett J., et al.
Publicado: (2021) -
Pharmacological ascorbate inhibits pancreatic cancer metastases via a peroxide-mediated mechanism
por: O’Leary, Brianne R., et al.
Publicado: (2020) -
Polymicrobial bacteremia and Strongyloides hyperinfection syndrome: Vigilance in patients on corticosteroids
por: Boyle, Evan, et al.
Publicado: (2022)